Marksans Pharma's Relonchem Gains UK MHRA Approval for Baclofen Tablets

Marksans Pharma Limited announced that its United Kingdom subsidiary company, Relonchem Limited, has achieved the marketing approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for tablets of Baclofen 10 mg. It is yet another achievement of Marksans' continued efforts towards widening its product line in regulated markets.

 

Key highlights:

 

1.Baclofen is prescribed to alleviate muscle spasms due to multiple sclerosis and spinal cord injury.

2.The drug will be produced at Marksans' cutting-edge UK plant, meeting high regulatory standards.

3.Relonchem already has more than 160 product licenses across the UK and Europe, consolidating Marksans' presence in these regions.

 

This clearance is part of Marksans Pharma's business strategy to build its presence in high-value therapeutic segments worldwide. Its emphasis on innovation and quality continues to propel growth, placing it among India's leading pharmaceutical exporters.

 

Sources: Marksans Pharma Regulatory Filing, Medical Dialogues, March 19, 2025